Discover the latest guidelines on appropriate diagnosis, evaluation, and risk stratification of non-muscle invasive bladder cancer (NMIBC) in this engaging and expert-led webcast. Learn about advances in the treatment landscape and emerging clinical data for novel chemoablative therapies in low-grade, intermediate-risk (LG-IR) NMIBC. Hear expert insights on considerations for integration of novel chemoablative therapies into clinical practice, including patient eligibility, treatment selection, and adverse event management.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/ask-experts-latest-advances-treatment-low-grade-intermediate-risk-non-muscle
- Start Date: 2024-12-30 06:00:00
- End Date: 2024-12-30 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.75 hours
AMA PRA Category 1 Credit™️: 0.75 hours
Nursing: 0.75 hours
Pharmacy: 0.75 hours - Commercial Support: Source: Urogen Pharma, Inc. - Amount: 23333.33 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest